logo-loader
viewGenprex, Inc.

Genprex boss Rodney Varner trumpets gene therapy company’s recent achievements

Varner said “we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research"

Genprex, Inc. - Genprex boss Rodney Varner trumpets gene therapy company’s recent achievements
He added: “These accomplishments have set the stage for us to continue on our path of growth and expansion"

Genprex Inc’s (NASDAQ:GNPX) chairman and chief executive, Rodney Varner has trumpeted the gene therapy company’s recent achievements, noting that it has completed part of its overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex immunogene therapy, to commercialization.

In a statement on Tuesday, Varner said: “Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initiatives.”

He added: “These accomplishments have set the stage for us to continue on our path of growth and expansion, enabling our efforts to bring our drug candidate to market for lung cancer patients who cannot benefit from today’s therapies.”

The recent achievements are outlined in the company’s newly launched, interactive corporate timeline, which can be found on Genprex’s website.

Contact the author at [email protected]

Quick facts: Genprex, Inc.

Price: 0.4801 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $7.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex's active drug ingredient validated by independent...

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher. Varner notes the study was published in the...

3 weeks, 5 days ago

2 min read